Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Torben Noerup Nielsen who wrote (29984)	1/8/2000 11:56:00 PM
From: Henry Niman	Respond to of 32384

Treating patients generally involves a risk/reward ratio and of course almost any slight benefit for advanced cancer would tip the scales in favor of reward. Earlier treatment makes side effects less tolerable and of course for treatment of diabetes, LLY passed on Targretin. I suspect that how Targretin is used off label is somewhat dependent on the upcoming clinical data, and since cancers other than CTCL will be off-label, I suspect that initial off label use will be for advanced patients who have failed approved therapies. I belive that eventually a rexinoid will be used to prevent breast cancer, but the drug will more likely be one of the second generation rexinoids, which LLY may announce soon. As far as filling the channels with Targretin are concerned, I would guess towards the end of this month or beginning of next month, but that is just a guess.